18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound.

Ryan Avery*, Phillip H. Kuo

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Intense FDG uptake by bone marrow following recent chemotherapy limits evaluation for osseous metastases. The impact of marrow rebound on accuracy of (18)F-fluoride PET/CT is unclear. A 73-year-old woman with breast cancer presented for restaging FDG PET/CT, which showed intense activity throughout almost the entire axial skeleton and no osseous metastases. An (18)F-fluoride PET/CT performed 7 days later identified multiple osseous metastases in the spine, ribs, and pelvis. This case demonstrates that (18)F-fluoride PET/CT should be considered for the evaluation of osseous metastases in patients with rebound marrow uptake on FDG PET/CT.

Original languageEnglish (US)
Pages (from-to)746-748
Number of pages3
JournalClinical nuclear medicine
Volume38
Issue number9
StatePublished - Sep 2013

Fingerprint

Sodium Fluoride
Bone Marrow
Fluorides
Breast Neoplasms
Neoplasm Metastasis
Ribs
Pelvis
Skeleton
Spine
Drug Therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{0379c992785a4229aa70199478989aed,
title = "18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound.",
abstract = "Intense FDG uptake by bone marrow following recent chemotherapy limits evaluation for osseous metastases. The impact of marrow rebound on accuracy of (18)F-fluoride PET/CT is unclear. A 73-year-old woman with breast cancer presented for restaging FDG PET/CT, which showed intense activity throughout almost the entire axial skeleton and no osseous metastases. An (18)F-fluoride PET/CT performed 7 days later identified multiple osseous metastases in the spine, ribs, and pelvis. This case demonstrates that (18)F-fluoride PET/CT should be considered for the evaluation of osseous metastases in patients with rebound marrow uptake on FDG PET/CT.",
author = "Ryan Avery and Kuo, {Phillip H.}",
year = "2013",
month = "9",
language = "English (US)",
volume = "38",
pages = "746--748",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound. / Avery, Ryan; Kuo, Phillip H.

In: Clinical nuclear medicine, Vol. 38, No. 9, 09.2013, p. 746-748.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound.

AU - Avery, Ryan

AU - Kuo, Phillip H.

PY - 2013/9

Y1 - 2013/9

N2 - Intense FDG uptake by bone marrow following recent chemotherapy limits evaluation for osseous metastases. The impact of marrow rebound on accuracy of (18)F-fluoride PET/CT is unclear. A 73-year-old woman with breast cancer presented for restaging FDG PET/CT, which showed intense activity throughout almost the entire axial skeleton and no osseous metastases. An (18)F-fluoride PET/CT performed 7 days later identified multiple osseous metastases in the spine, ribs, and pelvis. This case demonstrates that (18)F-fluoride PET/CT should be considered for the evaluation of osseous metastases in patients with rebound marrow uptake on FDG PET/CT.

AB - Intense FDG uptake by bone marrow following recent chemotherapy limits evaluation for osseous metastases. The impact of marrow rebound on accuracy of (18)F-fluoride PET/CT is unclear. A 73-year-old woman with breast cancer presented for restaging FDG PET/CT, which showed intense activity throughout almost the entire axial skeleton and no osseous metastases. An (18)F-fluoride PET/CT performed 7 days later identified multiple osseous metastases in the spine, ribs, and pelvis. This case demonstrates that (18)F-fluoride PET/CT should be considered for the evaluation of osseous metastases in patients with rebound marrow uptake on FDG PET/CT.

UR - http://www.scopus.com/inward/record.url?scp=84894553409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894553409&partnerID=8YFLogxK

M3 - Article

C2 - 23797230

AN - SCOPUS:84894553409

VL - 38

SP - 746

EP - 748

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 9

ER -